Kopran (KOPRAN) Stock Overview
An integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
KOPRAN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Kopran Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹189.63 |
| 52 Week High | ₹219.00 |
| 52 Week Low | ₹107.00 |
| Beta | 0.84 |
| 1 Month Change | -8.07% |
| 3 Month Change | 75.52% |
| 1 Year Change | 0.58% |
| 3 Year Change | 1.08% |
| 5 Year Change | -24.04% |
| Change since IPO | 125.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| KOPRAN | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -6.9% | 2.0% | -0.5% |
| 1Y | 0.6% | 10.6% | -2.3% |
Return vs Industry: KOPRAN underperformed the Indian Pharmaceuticals industry which returned 10.6% over the past year.
Return vs Market: KOPRAN exceeded the Indian Market which returned -2.3% over the past year.
Price Volatility
| KOPRAN volatility | |
|---|---|
| KOPRAN Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: KOPRAN's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: KOPRAN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 1,024 | Surendra Somani | www.kopran.com |
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti- helminthics, anti-acne, anti-infective, anti-thrombotic, sterile carbapenem, urological, neuromodulator, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular.
Kopran Limited Fundamentals Summary
| KOPRAN fundamental statistics | |
|---|---|
| Market cap | ₹9.16b |
| Earnings (TTM) | ₹257.31m |
| Revenue (TTM) | ₹6.81b |
Is KOPRAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KOPRAN income statement (TTM) | |
|---|---|
| Revenue | ₹6.81b |
| Cost of Revenue | ₹4.39b |
| Gross Profit | ₹2.42b |
| Other Expenses | ₹2.17b |
| Earnings | ₹257.31m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.33 |
| Gross Margin | 35.57% |
| Net Profit Margin | 3.78% |
| Debt/Equity Ratio | 28.8% |
How did KOPRAN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 01:38 |
| End of Day Share Price | 2026/06/25 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kopran Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Harini V. | FirstCall Research |